Comparable <scp>COVID</scp>‐19 outcomes with current use of <scp>GLP</scp>‐1 receptor agonists, <scp>DPP</scp>‐4 inhibitors or <scp>SGLT</scp>‐2 inhibitors among patients with diabetes who tested positive for <scp>SARS‐CoV</scp>‐2
Distribution of the number of citations over years.